SAN DIEGO, Aug. 8, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Hims & Hers Health, Inc. (NYSE: HIMS) securities between April 29, 2025 and June 23, 2025, both dates inclusive (the "Class Period"), have until Monday, August 25, 2025 to...
Related Questions
How should I adjust my risk management strategy for HIMS given the upcoming August 25, 2025 deadline?
Will the potential lead securities class action increase the likelihood of a settlement that could impact the company's financials?
How might this news influence the trading volume and liquidity of HIMS shares during the deadline period?
Is there any historical precedent for similar lawsuits affecting biotech or telehealth stocks that could guide expectations for HIMS?
How will the class action lawsuit deadline affect HIMS stock volatility in the short term?
Will the lawsuit potentially result in a material adverse change (MAC) that could trigger a price drop?
How might this development affect short interest and the potential for a short squeeze in HIMS?
Could the class action lead to additional regulatory scrutiny or disclosures that affect the stock price?
Are there any indications that institutional investors are adjusting their positions in response to the lawsuit announcement?
What is the potential impact of this legal development on HIMS's valuation multiples compared to its peers?